Scholarlink

<p>Children under five years of age are most vulnerable to the development of iron deficiency anemia (IDA) and its deleterious consequences. Several iron preparations have been studied in children. However, despite its proven efficacy in adults, the role of liposomal iron in children remains underexplored, with available studies primarily being retrospective and prophylactic. To compare the efficacy of liposomal iron versus ferrous ascorbate for the treatment of nutritional IDA in children aged 6 to 59 months. Design: double-blinded parallel randomized controlled trial. Setting: Pediatrics outpatient department. Subjects: Children aged 6 to 59 months with Nutritional IDA. Interventions: Participants were randomized to receive either ferrous ascorbate or liposomal iron for 12 weeks. Outcome: Change in hematological parameters between baseline and 12 weeks. Of 96 children enrolled, 81 (40 in the ferrous ascorbate group and 41 in the liposomal iron group) completed the follow-up. At 12 weeks, mean hemoglobin increased from 8.17 ±1.55 to 11.80 ±0.96&#xa0;g/dL in the ferrous ascorbate group and from 8.27 ±1.54 to 10.67 ±1.37&#xa0;g/dL in the liposomal group (between-group difference: 1.22&#xa0;g/dL; 95% CI: 0.65–1.65; <i>p</i>&lt;0.001), thus favouring ferrous ascorbate. Rise in ferritin and transferrin saturation values was also significantly higher in the ferrous ascorbate group (p value-0.001 each). At tested doses, liposomal iron did not offer any therapeutic advantage over ferrous ascorbate and had a similar safety profile in the present study. Given efficacy and ease of availability, ferrous ascorbate remains the preferred choice over liposomal iron for treating IDA in children.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Liposomal Iron Versus Ferrous Ascorbate for Treatment of Iron-Deficiency Anemia in Children Under 5: A Randomized Controlled Trial

  • 期刊论文

  • 发表日期：

    2026年1月7日

查看全文
  • Namita Mishra,
  • Altaf Ahmad Mir,
  • Vinita Paswan,
  • Rasna Gupta,
  • Mritunjay Kumar,
  • Amit Shukla

摘要

Children under five years of age are most vulnerable to the development of iron deficiency anemia (IDA) and its deleterious consequences. Several iron preparations have been studied in children. However, despite its proven efficacy in adults, the role of liposomal iron in children remains underexplored, with available studies primarily being retrospective and prophylactic. To compare the efficacy of liposomal iron versus ferrous ascorbate for the treatment of nutritional IDA in children aged 6 to 59 months. Design: double-blinded parallel randomized controlled trial. Setting: Pediatrics outpatient department. Subjects: Children aged 6 to 59 months with Nutritional IDA. Interventions: Participants were randomized to receive either ferrous ascorbate or liposomal iron for 12 weeks. Outcome: Change in hematological parameters between baseline and 12 weeks. Of 96 children enrolled, 81 (40 in the ferrous ascorbate group and 41 in the liposomal iron group) completed the follow-up. At 12 weeks, mean hemoglobin increased from 8.17 ±1.55 to 11.80 ±0.96 g/dL in the ferrous ascorbate group and from 8.27 ±1.54 to 10.67 ±1.37 g/dL in the liposomal group (between-group difference: 1.22 g/dL; 95% CI: 0.65–1.65; p<0.001), thus favouring ferrous ascorbate. Rise in ferritin and transferrin saturation values was also significantly higher in the ferrous ascorbate group (p value-0.001 each). At tested doses, liposomal iron did not offer any therapeutic advantage over ferrous ascorbate and had a similar safety profile in the present study. Given efficacy and ease of availability, ferrous ascorbate remains the preferred choice over liposomal iron for treating IDA in children.